One-year follow-up evaluation of radiological and respiratory findings and functional capacity in COVID-19 survivors without comorbidities

Ogun, Hamza; Gül, Merve; Akkoyunlu, Yasemin; Hayat, Esat; Gökbulut, Nuran; Sümbül, Bilge; Karaçöp, Handan Başel; Yurtsever, İsmail; Yabacı, Ayşegül; Kansu, Abdullah; Okyaltirik, Fatmanur

doi:10.1097/md.0000000000033960

Cited by 3 publications

(2 citation statements)

References 35 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although COVID-19 pneumonia is typically mild, it is fatal in patients with comorbidities such as diabetes, obesity, cancer, and chronic lung and cardiovascular diseases. [1,2] In addition to reverse transcription polymerase chain reaction (RT-PCR), diagnostic imaging such as plain radiography and computed tomography (CT) are important for diagnosing and treating COVID-19. [3,4] Chemerin is an adipocytokine with pleiotropic effects in humans.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of the chemerin level in coronavirus disease 2019 patients

Gokdemir,

Araç

et al. 2024

Medicine

View full text Add to dashboard Cite

Increased serum chemerin levels have been reported in several inflammatory diseases. Few studies have investigated the relationship between chemerin and clinical features of COVID-19. Thus, chemerin may modulate the development and progression of COVID-19. We compared the serum chemerin concentration between patients with and without SARS-CoV-2 infection and its association with the severity and prognosis of COVID-19 pneumonia. This is a prospective, single-center, cross-sectional study. We enrolled COVID-19 patients who presented to our tertiary hospital and healthy controls. The COVID-19 patients were conducted and the dates of symptom onset were recorded. After admission to the hospital and stabilization, blood samples were obtained for routine hemogram, biochemistry, and chemerin. The chemerin level was 37.93 ± 17.3 ng/mL in patients followed in the ICU, 29.41 ± 12.79 ng/mL in inpatients, 30.48 ± 10.86 ng/mL in outpatients, and 25.12 ± 9.82 ng/mL in healthy controls. The difference between patients treated in the ICU and healthy controls was significant (P < .001). The high-sensitivity C-reactive protein (hs-CRP), ferritin, procalcitonin (PCT), and D-dimer levels were significantly higher in the intensive care unit (ICU) group (P < .001). Moreover, the chemerin level of patients who died was significantly higher than that of those who survived (P < .001). The chemerin level was increased in COVID-19 patients and also increased with increasing disease severity. The chemerin level was higher in the COVID-19 patients than healthy controls and was significantly higher in patients who died compared to those who did not.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic significance of the chemerin level in coronavirus disease 2019 patients

Gokdemir,

Araç

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…In regard to pulmonary vasculature involvement, the role of post-pulmonary embolism (PE) clinical syndrome has been less widely considered, regardless of a proven thrombotic event during SARS-CoV-2 pneumonia. Most studies describe a progressive cardio-pulmonary improvement between 6 and 12 months after COVID-19 infection [ 1 , 4 – 8 ]. However, studies with longer (≥ 2 years) follow-up are required.…”

Section: Introductionmentioning

confidence: 99%

Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study

Faverio,

Paciocco,

Tassistro

et al. 2023

Intern Emerg Med

View full text Add to dashboard Cite

Short- and medium-term cardio-pulmonary sequelae after COVID-19 have been extensively studied. However, studies with longer follow-ups are required. This study aims to identify and characterise cardio-pulmonary sequelae, in patients hospitalised for SARS-CoV-2 pneumonia, at 24 months follow-up. This is a prospective, observational cohort study conducted on consecutive patients hospitalised for COVID-19 and acute respiratory failure. Patients were followed up at 24 months with complete pulmonary function tests (PFTs), 6-min walking test and a dyspnoea score (Modified Medical Research Council scale). A subgroup of patients with at least one clinical or functional sign suggestive of increased pulmonary pressures also underwent transthoracic echocardiography (TTE) to evaluate the presence of direct or indirect signs of pulmonary hypertension (PH). Ninety consecutive patients (74% men, median age 59.1 years) were enrolled in the study. In regard to PFTs, carbon monoxide diffusion capacity (DLCO) impairment was observed in 23 cases (26%), in all cases of mild entity. When considering the dyspnoea, 30 (34%) patients showed some degree of breathlessness. Forty patients underwent TTE. No patients had overt PH or chronic thromboembolic PH. However, all patients showed a hyperdynamic state of the right ventricle, and 8 (20%) patients had a decreased acceleration time on pulmonary valve, signs of increased pulmonary vasculature resistances and afterload elevation. At 24-month follow-up after severe COVID-19, DLCO and TTE prove to be the most sensitive tool to detect cardio-pulmonary sequelae. Dyspnoea is still present in about one-third of patients and requires a multidisciplinary approach.

show abstract

6-minute walk test in patients hospitalized with COVID-19

Kanaeva,

Karoli

2024

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. The 6 Minute Walk Test (6MWT) plays a key role in assessing functional exercise tolerance and prognosis for a wide range of chronic respiratory and cardiovascular diseases. In acute bronchopulmonary diseases, in particular COVID-19, there is practically no data on the possibilities of using 6MWT.Aim. To compare the results of a 6-minute walk test with clinical and laboratory parameters of patients hospitalized with new coronovirus infection.Materials and methods. The prospective, non-randomized comparative study sequentially enrolled 117 patients hospitalized with a confirmed diagnosis of COVID-19. Upon admission to the hospital, all patients performed 6MWT in accordance with international recommendations.Results. During the 6-minute trial, patients walked an average of 390 m (340.0; 420.0). In 96.6% of patients, there was a marked limitation of physical activity. Desaturation during the 6-minute test was registered in 25 (21.4%) patients. When conducting a correlation analysis, it was found that the result of the test with physical activity (the number of meters traveled) is associated with both initial and final SpO2, the presence of desaturation and the severity of dyspnea according to Borg, with the age of patients, the severity of the course of new coronovirus infection, laboratory signs of the activity of the inflammatory process upon admission. Relationships between the results of 6MWT (the number of meters covered and the % decrease in SpO2) and the duration of hospitalization, the maximum volume of lung damage according to CT data, the maximum severity of laboratory signs of inflammation (CRP, ferritin) during hospitalization, the need for oxygen therapy, the volume of anti-inflammatory therapy (doses of systemic glucocorticoids, pulse therapy with methylprednisolone). Patients with desaturation during exercise had a more severe course of the disease with a large amount of lung tissue damage, as well as higher laboratory indicators of the activity of the inflammatory process. It was also found that patients who desaturate during the exercise test more often required oxygen therapy during hospitalization, more often pulse therapy with methylprednisolone was performed.Conclusion. Patients with COVID-19 develop a decrease in physical performance, which is multifactorial. These include respiratory failure due to lung tissue damage, muscle weakness, nervous system damage (anxiety, depression), and systemic inflammation, which characterizes the severity of the infection and the associated immune response. The results of 6MWT may have a certain prognostic value in terms of the severity of the course of the disease, the severity of systemic inflammation, the need for oxygen therapy, and pulse therapy with glucocorticoids.

show abstract

One-year follow-up evaluation of radiological and respiratory findings and functional capacity in COVID-19 survivors without comorbidities

Cited by 3 publications

References 35 publications

Prognostic significance of the chemerin level in coronavirus disease 2019 patients

Prognostic significance of the chemerin level in coronavirus disease 2019 patients

Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study

6-minute walk test in patients hospitalized with COVID-19

Contact Info

Product

Resources

About